EIF5A2 and hepatocellular carcinoma: Overexpression of EIF5A2 has been detected in many solid tumors, including ovarian cancer [16], hepatocellular carcinoma [17, 18], non-small cell lung cancer [19], bladder cancer [20], melanoma [21], colorectal cancer [22], pancreatic adenocarcinoma [23] and ESCC [5].